Pfizer reports positive data from phase IV Toviaz trial

Pfizer has published new clinical data demonstrating the safety and efficacy of Toviaz among overactive bladder patients that have experienced suboptimal response to prior treatment.

Results from the new phase IV study reveal that Toviaz is able to reduce urge urinary incontinence in patients who failed to respond properly to Pfizer's Detrol LA, a commonly-prescribed treatment for this condition.

This could prove to be an important discovery for clinicians, as Detrol LA does not have a dosage option higher than 4 mg, whereas Toviaz can be increased to 8 mg based on individual response and tolerability.

Dr Steven Kaplan, professor of urology at Weill Cornell Medical College, said: "This study adds to the body of evidence supporting Toviaz as an effective treatment for patients with overactive bladder, including patients who may not have responded to Detrol LA."

Last December, the company published data from another Toviaz trial that demonstrated the treatment's efficacy among patients over the age of 65.